Disease Burden of Gastrointestinal Tumors in China From 1990 to 2021, an Analysis for the Global Burden of Disease Study 2021

Abstract

Objective: China faces a significant burden of gastrointestinal tumors driven by socioeconomic, environmental, and lifestyle factors. Using GBD2021 data, this study analyses epidemiological trends and disease burden for six major gastrointestinal tumor cancers (esophagus, gastric, colorectum, liver, pancreas, gallbladder and biliary tract) in China (1990–2021).

Methods: The GBD 2021 was used to extract the incidence, mortality, and disability-adjusted life years (DALYs) data of gastrointestinal tumors in China. Age-standardized rates (ASRs) and 95% uncertainty intervals (UIs) were calculated. Temporal trends were assessed by joinpoint regression analysis, and average annual percent change (AAPC) and annual percentage change (APC) were calculated and analyzed stratified by gender and age group.

Results: In 2021, China recorded 1.96 million new gastrointestinal cancer cases, with 1.35 million deaths and 33.07 million DALYs. Gastric cancer led in mortality, and colorectal cancer demonstrated the most rapid incidence growth (AAPC = 1.68). Significant reductions were observed in gastric cancer age-standardized mortality rates (ASMR) (AAPC = –2.44) and esophageal cancer age-standardized disability-adjusted life year rates (ASDR) (AAPC = –2.31). Gender disparities were particularly pronounced in esophageal cancer, with the male-to-female mortality ratio (M/F) escalating from 2.50 (1990) to 4.12 (2021). The age group with the highest mortality burden was 70–74, while the age group with the most significant loss of DALYs was 65–69.

Conclusion: China has significantly reduced gastrointestinal cancer burden, but gender and age disparities persist, necessitating targeted interventions. Future efforts should focus on tertiary prevention for high-risk groups, especially males and the elderly, while enhancing molecular subtyping and regional data stratification for precision cancer control.

Keywords

burden / gastrointestinal tumors / trends

References

[1] Global Burden of Disease 2019 Cancer Collaboration, J.M. Kocarnik, K. Compton, et al., “Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019,” JAMA Oncology 8 (2022): 420-444.

[2] J. Huang, D. E. Lucero-Prisno, L. Zhang, et al., “Updated Epidemiology of Gastrointestinal Cancers in East Asia,” Nature reviews Gastroenterology & hepatology 20, no. 5 (2023): 271-287.

[3] F. Bray, M. Laversanne, H. Sung, et al., “Global Cancer Statistics 2022: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians 74, no. 3 (2024): 229-263.

[4] GBD 2021 Causes of Death Collaborators, “Global Burden of 288 Causes of Death and Life Expectancy Decomposition in 204 Countries and territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403,no. 10440(2024): 2100-2132.

[5] G. B. D. Diseases and C. Injuries, “Global Incidence, Prevalence, Years Lived With Disability (YLDS), Disability-Adjusted Life-Years (DALYS), and Healthy Life Expectancy (HALE) for 371 Diseases and Injuries in 204 Countries and territories and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403, no. 10440 (2024): 2133-2161.

[6] GBD 2021 Risk Factors Collaborators, “Global Burden and Strength of Evidence for 88 Risk Factors in 204 Countries and 811 Subnational Locations, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021,” Lancet 403,no. 10440(2024): 2162-2203.

[7] GBD 2021 Demographics Collaborators, “Global Age-Sex-Specific Mortality, Life Expectancy, and Population Estimates in 204 Countries and Territories and 811 Subnational Locations, 1950-2021, and the Impact of the COVID-19 Pandemic: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2021,” Lancet 403, no. 10440(2024): 1989-2056.

[8] H. J. Kim, M. P. Fay, E. J. Feuer, et al., “Permutation Tests for Joinpoint Regression With Applications to Cancer Rates,” Statistics in Medicine 19, no. 3 (2000): 335-351.

[9] X. Gan, G. Dai, Y. Li, et al., “Intricate Roles of Estrogen and Estrogen Receptors in Digestive System Cancers: A Systematic Review,” Cancer Biol Med 21, no. 10 (2024): 898-915.

[10] U. C. McMenamin, P. Liu, A. T. Kunzmann, et al., “Circulating Sex Hormones Are Associated With Gastric and Colorectal Cancers but Not Esophageal Adenocarcinoma in the Uk Biobank,” American Journal of Gastroenterology 116, no. 3 (2021): 522-529.

[11] T. I. Mamun, S. Younus, and M. H. Rahman, “Gastric Cancer-Epidemiology, Modifiable and Non-modifiable Risk Factors, Challenges and Opportunities: An Updated Review,” Cancer Treatment and Research Communications 41 (2024): 100845.

[12] S. Jun, H. Park, U. J. Kim, et al., “The Combined Effects of Alcohol Consumption and Smoking on Cancer Risk by Exposure Level: A Systematic Review and Meta-analysis,” Journal of Korean Medical Science 39, no. 22 (2024): e185.

[13] M. Arnold, C. C. Abnet, R. E. Neale, et al., “Global Burden of 5 Major Types of Gastrointestinal Cancer,” Gastroenterology 159, no. 1 (2020): 335-349. e315.

[14] P. Rawla, T. Sunkara, and A. Barsouk, “Epidemiology of Colorectal Cancer: Incidence, Mortality, Survival, and Risk Factors,” Przegląd Gastroenterologiczny 14, no. 2 (2019): 89-103.

[15] V. Bouvard, D. Loomis, K. Z. Guyton, et al., “Carcinogenicity of Consumption of Red and Processed Meat,” The Lancet Oncology 16, no. 16 (2015): 1599-1600.

[16] V. Fedirko, I. Tramacere, V. Bagnardi, et al., “Alcohol Drinking and Colorectal Cancer Risk: An Overall and Dose-Response Meta-Analysis of Published Studies,” Annals of Oncology 22, no. 9 (2011): 1958-1972.

[17] J. K. Y. Hooi, W. Y. Lai, W. K. Ng, et al., “Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis,” Gastroenterology 153, no. 2 (2017): 420-429.

[18] C. Allemani, T. Matsuda, V. Di Carlo, et al., “Global Surveillance of Trends in Cancer Survival 2000-14 (concord-3): Analysis of Individual Records for 37 513 025 Patients Diagnosed With One of 18 Cancers From 322 Population-Based Registries in 71 Countries,” Lancet 391, no. 10125 (2018): 1023-1075.

[19] M. Arnold, M. J. Rutherford, A. Bardot, et al., “Progress in Cancer Survival, Mortality, and Incidence in Seven High-income Countries 1995-2014 (ICBP SURVMARK-2): A Population-Based Study,” The Lancet Oncology 20, no. 11 (2019): 1493-1505.

[20] J. K. Jun, K. S. Choi, H. Y. Lee, et al., “Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality,” Gastroenterology 152, no. 6 (2017): 1319-1328. e1317.

[21] L. Yang, L. Feng, Y. Zhu, et al., “Reducing the Global Cancer Burden With Gastrointestinal Screening: China's 30 Years Practice,” Cancer Biology & Medicine 21, no. 3 (2024): 204-212.

[22] R. Chen, Y. Liu, G. Song, et al., “Effectiveness of One-Time Endoscopic Screening Programme in Prevention of Upper Gastrointestinal Cancer in China: A Multicentre Population-Based Cohort Study,” Gut 70, no. 2 (2021): 251-260.

[23] A. L. Cox, M. H. El-Sayed, J. H. Kao, et al., “Progress Towards Elimination Goals for Viral hepatitis,” Nature reviews Gastroenterology & Hepatology 17, no. 9 (2020): 533-542.

[24] G. Cao, J. Liu, and M. Liu, “Trends in Mortality of Liver Disease due to Hepatitis B in China From 1990 to 2019: Findings From the Global Burden of Disease Study,” Chinese Medical Journal 135, no. 17 (2022): 2049-2055.

[25] X. Tang, P. Wang, S. Huang, et al., “Trend of Gastrointestinal and Liver Diseases in china: Results of the Global Burden of Disease Study,” Chinese Medical Journal 137, no. 19 (2019): 2358-2368.

[26] B. McMahon, C. Cohen, R. S. Brown, et al., “Opportunities to Address Gaps in Early Detection and Improve Outcomes of Liver Cancer,” JNCI Cancer Spectr 7, no. 3 (2023).

[27] A. P. Klein, “Pancreatic Cancer Epidemiology: Understanding the Role of Lifestyle and Inherited Risk Factors,” Nature reviews Gastroenterology & Hepatology 18, no. 7 (2021): 493-502.

[28] L. D. Wood and R. H. Hruban, “Pathology and Molecular Genetics of Pancreatic Neoplasms,” Cancer Journal 18, no. 6 (2012): 492-501.

[29] D. Li, H. Tang, M. M. Hassan, et al., “Diabetes and Risk of Pancreatic Cancer: A Pooled Analysis of Three Large Case-Control Studies,” Cancer Causes & Control 22, no. 2 (2011): 189-197.

[30] Z. Zheng, R. Zheng, Y. He, et al., “Risk Factors for Pancreatic Cancer in China: A Multicenter Case-Control Study,” Journal of Epidemiology 26, no. 2 (2016): 64-70.

[31] J. D. Mizrahi, R. Surana, J. W. Valle, et al., “Pancreatic Cancer,” Lancet 395, no. 10242 (2020): 2008-2020.

[32] N. B. Henrikson, E. J. Aiello Bowles, P. R. Blasi, et al., “Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the Us Preventive Services Task Force,” JAMA 322, no. 5 (2019): 445-454.

[33] S. H. Semnani, S. Besharat, N. Abdolahi, et al., “Esophageal Cancer in Northeastern Iran,” Indian Journal of Gastroenterology 24, no. 5 (2005): 224.

[34] M. Arnold, I. Soerjomataram, J. Ferlay, et al., “Global Incidence of Oesophageal Cancer by Histological Subtype in 2012,” Gut 64, no. 3 (2015): 381-387.

[35] S. Lander, E. Lander, and M. K. Gibson, “Esophageal Cancer: Overview, Risk Factors, and Reasons for the Rise,” Current Gastroenterology Reports 25, no. 11 (2023): 275-279.

[36] H. Zeng, W. Chen, R. Zheng, et al., “Changing Cancer Survival in China During 2003-15: A Pooled Analysis of 17 Population-Based Cancer Registries,” The Lancet Global Health 6, no. 5 (2018): e555-e567.

[37] W. Q. Wei, Z. F. Chen, Y. T. He, et al., “Long-term Follow-Up of a Community Assignment, One-time Endoscopic Screening Study of Esophageal Cancer in china,” Journal of Clinical Oncology 33, no. 17 (2015): 1951-1957.

[38] C. Xia, P. Basu, B. S. Kramer, et al., “Cancer Screening in china: A Steep Road From Evidence to Implementation,” Lancet Public Health 8, no. 12 (2023): e996-e1005.

[39] J. C. Roa, P. Garcia, V. K. Kapoor, et al., “Gallbladder Cancer,” Nature reviews Disease primers 8, no. 1 (2022): 69.

[40] Y. Li, J. Zhang, and H. Ma, “Chronic Inflammation and Gallbladder Cancer,” Cancer Letters 345, no. 2 (2014): 242-248.

[41] A. Lamarca, J. Edeline, and L. Goyal, “How I Treat Biliary Tract Cancer,” ESMO Open 7, no. 1 (2022): 100378.

RIGHTS & PERMISSIONS

2025 The Author(s). Journal of Evidence-Based Medicine published by Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.